Kymera Therapeutics

Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors

Read more

Expression & Characterization of Novel Tissue Selective E3 Ligases

Read more

MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine

Read more

Non-Clinical Safety Considerations when Developing Targeted Protein Degraders

Read more

Drugging Tissue Restricted E3 Ligases for TPD-based Precision Medicine

Read more

Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics

Read more

KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

Read more

Undruggable Leaders Forum, September 15-16, 2021

Read more

The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation

Read more

Marking Kymera’s 5-Year Anniversary

Read more